Antimicrobial prophylactic treatment of recurrent UTI is limited by emerging resistance, antibiotic allergies and intolerances. Intravesical aminoglycoside instillations (IAI) have been shown to reduce recurrence rate, without a short-term decline in kidney function or hearing. Thus far, treatment satisfaction has not yet been assessed, while this may play an important role in treatment adherence and persistence. Moreover, there is no data on the long-term safety of IAI, e.g. regarding the development of (pre)malignant bladder lesions.
Study Type
OBSERVATIONAL
Enrollment
44
Overnight instillation of an aminoglycoside (CIC), varying treatment regimens
Leiden University Medical Center
Leiden, South Holland, Netherlands
Treatment satisfaction regarding intravesical aminoglycoside instillations (IAI)
Measured with Treatment Satisfaction Questionnaire for Medication version II (TSQM-II), value ranging from 0 to 100 (with a score of 100 indicating the highest treatment satisfaction)
Time frame: 1 year
Time to first UTI recurrence after initiation of IAI
Time frame: First 6 months of IAI
Number of UTI recurrences
Time frame: First 6 months of IAI
Number of UTI recurrences that are treated with IAI alone (no systemic antimicrobial therapy)
Time frame: First 6 months of IAI
Number of patients that wish to (dis)continue IAI
Time frame: 6 months after initiation of IAI
Proportion of patients that have a UTI episode caused by the same MDRO uropathogen as before start of IAI
Time frame: 6 months after initiation of IAI
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.